NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Douglas Carr, MD; Russell Huffman, PMHNP; Caryn Mickelson, PharmD; Robin Moody; William Origer, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Trevor Douglass, DC, MPH; Amanda Parish, LCSW; Jennifer Bowen; Dee Weston, JD; Kyle Hamilton

Audience: Craig Sexton, GSK*; Lynda Finch, Biogen*; Nirmal Ghuman, Janssen*; Basmina Parmakhtiar, Traverse Therapeutics*; Mark Kantor, AllCare Health; Philip Santa Maria; Brandon Walker, Servier; Jim Slater, CareOregon; William Lam, Madrigal; Ken Liu, Madrigal; Daria Meleshkina, EOCCO; Rick Dabner; Jason Kniffen; Saghi Maleki; Sami Nasrawi; Jon Buncab, Traverese; Susan Lakey Kevo; Kate Ramsay, EOCCO; Cecilia Stewart, EOCCO; Jeffrey Baptista, EOCCO; Amanda Pan, EOCCO; Bill McDougall, Biogen; Melissa Snider, Gilead; Matt Worthy, OHSU; Tiina Andrews, UHA; Brandie Feger, Advanced Health CCO; Lori McDermott, Viking HCS; Georgette Dzwilewski, Indivior; Michele Sabados, Alkermes; Shauna Wick, Trillium; Jeff White, Sumitomo; Lisa Pulver J&J;

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and October 2023 Minutes presented by Roger Citron, RPh
   ACTION: Motion to approve, 2nd, all in favor
D. Department Update and recognition of P&T Committee members with terms expiring
   provided by Trevor Douglass, DC, MPH

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Report
B. Ycanth™ (cantharidin) Abbreviated Drug Review (ADR)
   Recommendation:
   - Apply Drugs for Non-funded Conditions prior authorization criteria to limit use to
     funded indications
C. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Aphexda™ (motixafortide); and Ojjaara (momelotinib) to table 1 in the Oncology
     Agents prior authorization (PA) criteria
D. Orphan Drug Policy Updates
   Recommendation:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of
     Rivfloza™ (nedosiran) based on FDA-approved labeling
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD
B. RetroDUR Report: Dave Engen, PharmD
C. Oregon State Drug Review: Kathy Sentena, PharmD
   1. Buprenorphine: Place in Therapy for Chronic Pain
   2. Update on the Use of SGLT-2 Inhibitors
   3. 2023 Global Initiative for Chronic Obstructive Lung Disease Report: Focus on
      Revised Recommendations for Inhaler Products
IV. DUR NEW BUSINESS

A. Nexletol® (bempedoic acid) PA Update: Megan Herink, PharmD
   Recommendation:
   - Update the clinical PA criteria to include coverage for bempedoic acid for high-risk primary prevention in patients with documented statin intolerance already on ezetimibe
   ACTION: Motion to approve, 2nd, all in favor

B. Over-the-Counter Policy Proposal: Sarah Servid, PharmD
   Recommendations:
   - Update operating procedures to clarify policy and process to maintain a list of PDL classes that include covered OTC medications
   - Update the OTC list to include new daily contraceptives
   ACTION: Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Topical Moisturizers Class Review: Sarah Servid, PharmD
   Recommendations:
   - Cover select topical moisturizers with PA to limit coverage to funded conditions
   - Update benefit plan exclusion criteria and review exceptions process
   - No PDL recommendations for specific products based on the clinical evidence
   - Evaluate costs in executive session
   ACTION: The Committee recommended requiring PA only for non-preferred agents
   Motion to approve, 2nd, all in favor

B. Erythropoiesis Stimulating Agents (ESA) Literature Scan: Deanna Moretz, PharmD
   Recommendations:
   - No PDL changes recommended based on the review of recently published evidence
   - Retire ESA PA criteria due to limited POS utilization
   - Evaluate costs in executive session
   ACTION: Motion to approve, 2nd, all in favor

C. Jesduvroq™ (daprodustat) New Drug Evaluation (NDE): Sara Fletcher, PharmD
   Recommendations:
   - Maintain daprodustat as non-preferred on the PDL
   - Implement PA criteria to ensure safe and appropriate use
   Public Comment: Craig Sexton, GSK
   ACTION: Motion to approve, 2nd, all in favor
D. Antidepressants Class Update & Zurzuvae™ (zuranolone) NDE: Kathy Sentena, PharmD

Recommendations:
- No PDL changes recommended based on the review of recently published evidence
- Implement safety edit for zuranolone to ensure product use is limited to populations with established safety and efficacy
- Evaluate costs in executive session

Public Comment: Lynda Finch, Biogen; Nirmal Ghuman, Janssen

ACTION: The Committee recommended adding language to permit zuranolone use in moderate to severe post-partum depression when a provider submits the diagnosis of major depressive disorder

Motion to approve, 2nd, all in favor

E. Filspari™ (sparsentan) NDE: Dave Engen, PharmD

Recommendations:
- Make sparsentan non-preferred on the PDL
- Implement PA criteria to ensure safe and appropriate use

Public Comment: Basmina Parmakhtiar, Travere Therapeutics

ACTION: Motion to approve, 2nd, all in favor

F. Oral and Topical Antifungals Class Update & Vivjoya™ (oteseconazole) NDE: Kathy Sentena, PharmD

Recommendations:
- No PDL changes recommended based on the review of recently published evidence
- Combine the topical and vaginal antifungals agents into one class
- Maintain oteseconazole as non-preferred and subject to PA
- Evaluate costs in executive session

ACTION: The Committee recommended requiring a trial/failure/contraindication to oral fluconazole prior to approval of oteseconazole adding language to permit zuranolone

Motion to approve, 2nd, all in favor

---

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Russel Huffman, PMHNP; Caryn Mickelson, PharmD; Robin Moody; William Origer, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton
VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Topical Moisturizers Class Recommendation:
   - Cover creams, lotions, ointments. Do not cover other OTC formulations or OTCs costing more than $1 per gram or mL
   - Make moisturizers preferred if they cost less than $0.05 per gram or mL. Make all other moisturizers non-preferred
   - Until they are reviewed by P&T, new products will be added as non-preferred or non-covered based on current recommendations
   ACTION: Motion to approve, 2nd, all in favor

B. Erythropoiesis Stimulating Agents
   Recommendations: Make no changes to the PDL
   ACTION: Motion to approve, 2nd, all in favor

C. Antidepressants Class
   Recommendations: Make no changes to the PDL
   ACTION: Motion to approve, 2nd, all in favor

D. Oral and Topical Antifungals
   Recommendations: Make no changes to the oral antifungal agents and make terconazole suppositories, butoconazole, miconazole 1 kits and miconazole 3 kits, miconazole suppositories (Miconozole 3) and clotrimazole (Vaginal 3-day) non-preferred. Make other vaginal formulations preferred
   ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN